In:
European Journal of Clinical Investigation, Wiley, Vol. 44, No. 12 ( 2014-12), p. 1239-1245
Abstract:
The concept of leukaemic stem cells ( LSC s) has been developed to explain the complex cellular hierarchy and biology of leukaemias and to screen for pivotal targets that can be employed to improve drug therapies through LSC eradication in these patients. Some of the newly discovered LSC markers seem to be expressed in a disease‐specific manner and may thus serve as major research tools and diagnostic parameters. A useful LSC marker in chronic myeloid leukaemia ( CML ) appears to be CD 26, also known as dipeptidylpeptidase IV . Expression of CD 26 is largely restricted to CD 34 + / CD 38 − LSC s in BCR / ABL 1 + CML , but is not found on LSC s in other myeloid or lymphoid neoplasms, with the exception of lymphoid blast crisis of CML , BCR / ABL 1 p210 + acute lymphoblastic leukaemia, and a very few cases of acute myeloid leukaemia. Moreover, CD 26 usually is not expressed on normal bone marrow (BM) stem cells. Functionally, CD 26 is a cytokine‐targeting surface enzyme that may facilitate the mobilization of LSC s from the BM niche. In this article, we review our current knowledge about the biology and function of CD 26 on CML LSC s and discuss the diagnostic potential of this new LSC marker in clinical haematology.
Type of Medium:
Online Resource
ISSN:
0014-2972
,
1365-2362
DOI:
10.1111/eci.2014.44.issue-12
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2004971-7